Literature DB >> 7903492

Combination therapy protects ischemic brain in rats. A glutamate antagonist plus a gamma-aminobutyric acid agonist.

P D Lyden1, L Lonzo.   

Abstract

BACKGROUND AND
PURPOSE: The excitotoxic effects of glutamate can be blocked almost completely with gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, in cell culture, tissue slices, and in some animal models. After stroke in rats, we showed previously that an agonist of GABA, muscimol, was as neuroprotective as MK-801, an antagonist of glutamate. To obtain further neuroprotection and to avoid the side effects associated with high doses of MK-801, we wanted to assess the efficacy of the two agents in combination.
METHODS: Treatment was administered 5 minutes after embolic cerebral ischemia in Sprague-Dawley rats. The subjects were rated using a neurological evaluation 48 hours later. Visual-spatial learning was measured 8 to 10 weeks after stroke, after which we measured the volume of each cerebral hemisphere and several large cerebral compartments. Treatment groups included saline (n = 27), MK-801 1.0 mg/kg (n = 23), muscimol 1.0 mg/kg (n = 17), and both agents together using a dose of 0.5 mg/kg each (n = 25).
RESULTS: A probit analysis of the neurological ratings revealed a protective effect of muscimol used alone (MK-801 potency ratio, 2.0; P = NS; muscimol potency ratio, 4.0; P < .05) and a protective effect of the combination (potency ratio, 5.0; P < .05). Focal ischemia caused a moderate to severe delay in the acquisition of visual-spatial information, which was completely eliminated by the combination treatment but only partially ameliorated with MK-801 or muscimol alone. Ischemia reduced the cerebral hemisphere volume from 0.42 mm3 to 0.34 mm3 (P < .0001), the volume density of cortex from 22% to 17% of total cerebral volume (P < .01), and that of hippocampus from 4.3% to 3.0% (P < .05). Only the combination was neuroprotective, as measured by the ratio of the lesioned to the contralateral hemisphere volume (P = .013). The combination treatment and MK-801 protected the hemisphere volume, the cortex, and the hippocampus and reduced the size of visible infarction.
CONCLUSIONS: Combination therapy, using a glutamate antagonist and a GABA-A agonist, appeared to protect the brain and ameliorate a defect in learning behavior after stroke. The combination may have been more effective than either agent used alone, although further study of higher doses is needed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7903492     DOI: 10.1161/01.str.25.1.189

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  11 in total

Review 1.  Trends and future developments in the pharmacological treatment of acute ischaemic stroke.

Authors:  G J del Zoppo; S Wagner; M Tagaya
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

2.  Run-down of the GABAA response under experimental ischaemia in acutely dissociated CA1 pyramidal neurones of the rat.

Authors:  N Harata; J Wu; H Ishibashi; K Ono; N Akaike
Journal:  J Physiol       Date:  1997-05-01       Impact factor: 5.182

3.  Failure of ischemic neuroprotection by potentiators of gamma-aminobutyric acid.

Authors:  Ken Madden; Wayne Clark; Nicola Lessov
Journal:  Clin Med Res       Date:  2003-04

4.  Intraspinal transplantation of GABAergic neural progenitors attenuates neuropathic pain in rats: a pharmacologic and neurophysiological evaluation.

Authors:  Stanislava Jergova; Ian D Hentall; Shyam Gajavelli; Mathew S Varghese; Jacqueline Sagen
Journal:  Exp Neurol       Date:  2011-12-13       Impact factor: 5.330

Review 5.  What animal models have taught us about the treatment of acute stroke and brain protection.

Authors:  S H Ahmed; A Y Shaikh; Z Shaikh; C Y Hsu
Journal:  Curr Atheroscler Rep       Date:  2000-03       Impact factor: 5.113

Review 6.  Limiting neurological damage after stroke: a review of pharmacological treatment options.

Authors:  S J Read; T Hirano; S M Davis; G A Donnan
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

7.  Differential changes in pyridoxine 5'-phosphate oxidase immunoreactivity and protein levels in the somatosensory cortex and striatum of the ischemic gerbil brain.

Authors:  In Koo Hwang; Ki-Yeon Yoo; Dae Won Kim; Oh-Shin Kwon; Soon Sung Lim; Il-Jun Kang; Soo Young Choi; Moo-Ho Won
Journal:  Neurochem Res       Date:  2008-02-21       Impact factor: 3.996

8.  Neuroprotection of GluR5-containing kainate receptor activation against ischemic brain injury through decreasing tyrosine phosphorylation of N-methyl-D-aspartate receptors mediated by Src kinase.

Authors:  Jie Xu; Yong Liu; Guang-Yi Zhang
Journal:  J Biol Chem       Date:  2008-08-04       Impact factor: 5.157

9.  MK-801 attenuates lesion expansion following acute brain injury in rats: a meta-analysis.

Authors:  Nan-Xing Yi; Long-Yun Zhou; Xiao-Yun Wang; Yong-Jia Song; Hai-Hui Han; Tian-Song Zhang; Yong-Jun Wang; Qi Shi; Hao Xu; Qian-Qian Liang; Ting Zhang
Journal:  Neural Regen Res       Date:  2019-11       Impact factor: 5.135

Review 10.  Cerebroprotection for Acute Ischemic Stroke: Looking Ahead.

Authors:  Patrick D Lyden
Journal:  Stroke       Date:  2021-07-22       Impact factor: 10.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.